H. Takeuchi et al., Implantation of xenografts into the parkinsonian rat brain after portal venous administration of xenogeneic donor spleen cells, J NEUROSURG, 94(5), 2001, pp. 775-781
Object. The purpose of the present study was to examine the effect of pretr
ansplantation portal venous immunization with ultraviolet B (UVB)-treated d
onor spleen cells on neural xenograft transplantation.
Methods. Cells from a murine catecholaminergic cell line derived from the B
6/D2 F1 mouse, CATH.a, were used as a xenograft. Thirty hemiparkinsonian ra
ts were divided into three different treatment groups. Group 1 received sal
ine in;he dopamine-denervated striatum; Group 2 received xenograft cells; a
nd Group 3 received portal venous administration of UVB-irradiated B6/D2 F1
splenocytes 7 days before receiving xenograft cells. Xenograft function wa
s determined by reviewing apomorphine-induced rotation at 2-week intervals,
and xenograft survival was examined at 4 and 12 weeks after transplantatio
n by immunohistochemical staining for murine tyrosine hydroxylase (THase).
Rotational behavior was improved in both xenograft-transplanted groups (Gro
ups 2 and 3); however, the animals in Group 3 displayed a significantly red
uced rotational behavior compared with Group 2. In Group 2, many inflammato
ry cells and a few THase-positive cells were found at the graft sites 4 wee
ks after transplantation. In Group 3. however, a large number of THase-posi
tive cells were found with few inflammatory cells. The THase-positive cells
disappeared in the Group 2 rats at 12 weeks. but remained in Group 3 anima
ls. In Group 3 rats proliferation of spleen cells in a mixed lymphocyte rea
ction was suppressed in a donor-specific fashion.
Conclusions. This work demonstrates improved neural xenograft survival and
function by pretransplantation portal venous immunization with UVB-irradiat
ed xenogeneic donor splenocytes. On the basis of these findings, the author
s suggest the possibility of creating donor-specific immunological toleranc
e in the brain by administration of xenogeneic donor lymphocytes via the po
rtal vein.